首页> 外文期刊>Open Journal of Regenerative Medicine >Treatment of a mouse model of collagen antibody-induced arthritis with human adipose-derived secretions
【24h】

Treatment of a mouse model of collagen antibody-induced arthritis with human adipose-derived secretions

机译:用人脂肪来源的分泌物治疗胶原蛋白抗体诱导的关节炎的小鼠模型

获取原文
       

摘要

The use of adipose-derived cells as a treatment for a variety of diseases is becoming increasingly common. These therapies include the use of cultured mesenchymal stem cells (MSCs) and freshly isolated stromal vascular fraction (SVF) alone, or in conjunction with other cells such as adipocytes. There is a substantial amount of literature published on the therapeutic properties of MSCs and their secretions as the main driver of their therapeutic effect. However, there is little data available on the therapeutic potential of secretions from SVF, either with or without adipocytes. We investigated the ability of secretions from human adipose SVF alone and the SVF co-cultured with adipocytes as a proxy for cell therapy, to ameliorate an inflammatory disorder. This ethics approved study involved the treatment of collagen antibody-induced arthritis (CAIA) in mice with secretions from SVF, SVF co-cultured with adipocytes, or a vehicle control via both intravenous (IV) and intramuscular (IM) routes. Treatment outcome was assessed by paw volume, ankle size and clinical arthritis score measurements. Serum samples were obtained following euthanasia and analysed for a panel of 32 mouse cytokines and growth factors. The dose and timing regime used for the IM administration of both human secretion mixtures did not significantly ameliorate arthritis in this model. The IV administration of SVF adipocyte co-culture secretions reduced the paw volume, and significantly reduced the ankle size and clinical arthritis score when compared to the IV vehicle control mice. This was a superior therapeutic effect than treatment with SVF secretions. Furthermore, treatment with SVF adipocyte coculture secretions resulted in a significant reduction in serum levels of key cytokines, IL-2 and VEGF, involved in the pathogenesis of rheumatoid arthritis. Therefore, the SVF cocultured with adipocytes is an attractive therapeutic for inflammatory conditions.
机译:脂肪细胞作为多种疾病的治疗方法正变得越来越普遍。这些疗法包括单独使用培养的间充质干细胞(MSCs)和新鲜分离的基质血管部分(SVF),或与其他细胞(如脂肪细胞)结合使用。关于MSC的治疗特性及其分泌作为其治疗作用的主要驱动力,已有大量文献发表。但是,关于有或没有脂肪细胞的SVF分泌物治疗潜力的数据很少。我们调查了人类脂肪SVF和与脂肪细胞共培养的SVF的分泌能力,以作为细胞疗法的替代品,以减轻炎症性疾病。该伦理学批准的研究涉及通过静脉内(IV)和肌肉内(IM)途径用SVF分泌物,与脂肪细胞共培养的SVF或媒介物对照治疗小鼠胶原抗体诱导的关节炎(CAIA)。通过爪子体积,脚踝大小和临床关节炎评分测量评估治疗结果。安乐死后获得血清样品,并分析一组32种小鼠细胞因子和生长因子。用于IM给药两种人类分泌混合物的剂量和时间安排在该模型中并未显着改善关节炎。与静脉注射媒介物对照小鼠相比,静脉注射SVF脂肪细胞共培养物分泌物减少了爪子的体积,并显着减小了踝关节的大小和临床关节炎评分。这是比用SVF分泌物治疗更好的治疗效果。此外,用SVF脂肪细胞共培养物分泌物治疗可导致类风湿关节炎发病机理中关键细胞因子IL-2和VEGF的血清水平显着降低。因此,与脂肪细胞共培养的SVF是治疗炎症的诱人疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号